Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Clinical trial NCT06384560 · RECRUITING

Trial details

NCT number: NCT06384560
Sponsor: Amsterdam UMC, location VUmc
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Localized Pancreatic Adenocarcinoma Borderline Resectable Pancreatic Adenocarcinoma Resectable Pancreatic Adenocarcinoma

Start date: 2024-09-23
Primary completion: 2028-03-01
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.